Bowl of medicines

Analysis

Life Sciences & Health Care M&A update: Q4 2018

The Life Science and Health Care industry has historically faced challenges when it pertains to keeping cost low while delivering high-quality health care services. With the advancement of 3D printing in the health care space, stakeholders will be able to drive improved health related services, while reducing costs. Life Sciences & Health Care mergers and acquisitions (M&A) update provides Deloitte Corporate Finance LLC insights and market data analysis that shed light on M&A trends in the Life Sciences and Health Care industry.

How 3D printing can revolutionize health care

Health plans, providers, life sciences companies, and the government are increasingly facing rising costs and inconsistent outcomes. They are working to achieve the triple goal of improving care, improving health, and reducing costs. Advancements in 3D printing technology offers stakeholders across the Life Sciences and Health Care (LSHC) space a triple-pronged approach to help achieve these goals.

3D printing is a process that works by building solid, three-dimensional objects from a digital model, adding materials layer by layer, rather than producing a final product by cutting away excess. 3D printing technologies are driving innovation across the health care continuum, with significant and wide-ranging benefits including:1

  • Greater access to health care products and technology2
  • Availability of specialized medical devices3
  • Improved procedural outcomes4

Key 3D printing M&A value drivers

  • Streamlining supply chains: The efficient and scalable benefits of 3D printing technologies can decrease medical costs and enable health care providers to more effectively compete in the marketplace.
  • Mass product customization: Harnessing the power of 3D printing technology allows healthcare professionals to produce previously unavailable or outdated medical devices and specialized products.
  • Large runway for growth: As the barriers for widespread adoption of 3D printing technologies are lowered and regulations loosened, the global 3D printing market is projected to grow at a compound annual growth rate (CAGR) of 24 percent through 2023.5

This newsletter is a periodic compilation of certain capital markets information. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have “long” and “short” positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

References

1 Deloitte Center for Health Solutions (DCHS). Master Protocol Clinical Trial Drug Development Process. October 2018.

2 Ibid.

Did you find this useful?